Browse Research
Filter Results
- By Specialty
- All Specialties
- Health Policy and Reform (106)
- Cardiology (27)
-
Primary Care/
Hospitalist/
Clinical Practice (19) - Hematology/Oncology (18)
- Infectious Disease (17)
- Endocrinology (16)
- Medical Practice, Training, and Education (15)
- Geriatrics/Aging (13)
- Surgery (13)
-
Pulmonary/
Critical Care (12) - Genetics (10)
- Medical Ethics (10)
- Pediatrics (10)
- Emergency Medicine (8)
- Neurology/Neurosurgery (7)
- Obstetrics/Gynecology (7)
- Psychiatry (7)
- Nephrology (3)
- Allergy/Immunology (2)
- Dermatology (1)
- Gastroenterology (1)
- Medical Statistics (1)
- Orthopedics (1)
- Rheumatology (1)
- By Article Type
- All Types
- Original Article (80)
- Special Article (1)
- By Date
- Past 10 years
- Past 20 years
- Past 50 years
- Past 100 years
- Complete archive (1812-present)
- Specific date range
Sort By:
- Newest
- Oldest
- Most Viewed
- Most Cited
Special Article
Health and Economic Implications of HPV Vaccination in the United States
In the United States, cervical cancer developed in an estimated 11,150 women and caused death in 3600 women in 2007. Infection with high-risk "oncogenic" types of human papillomavirus (HPV) is the cause of 100% of cervical cancers, 90% of anal cancers, 40% of vulvar and vaginal cancers, at least…
- Free Full Text
The authors conducted a cost-effectiveness analysis of human papillomavirus (HPV) vaccination in the United States and estimated that vaccinating 12-year-old girls would cost $43,600 per quality-adjusted life-year (QALY) gained, as compared with the current screening practice. If vaccine-induced immunity wanes after 10 years, HPV vaccination would be much less cost-effective (>$140,000 per QALY).
Page
- 1
